Braidwell LP Reduces Holdings in BioAge Labs, Inc. $BIOA

Key Points

• Braidwell LP cut its BioAge Labs stake by 13.9% in the second quarter, selling 167,458 shares and retaining 1.03 million shares worth approximately $25.3 million. Several other institutional investors, including Yiheng Capital and Wellington Management, initiated or increased positions.
• BioAge Labs reported a quarterly loss of $0.58 per share, beating estimates of a $0.65 loss, on $2.45 million in revenue. The stock opened at $9.73, well below its 52-week high of $25.95, while profitability metrics remained deeply negative.
• Analyst sentiment is generally positive, with six Buy ratings and one Sell rating, producing a consensus “Moderate Buy” rating and an average price target of $36.57; individual targets range from $21 to $40.

Braidwell LP lessened its position in BioAge Labs, Inc. (NASDAQ:BIOA - Free Report) by 13.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,033,129 shares of the company's stock after selling 167,458 shares during the quarter. Braidwell LP owned 2.25% of BioAge Labs worth $25,322,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in BIOA. Yiheng Capital Management L.P. purchased a new stake in BioAge Labs in the 2nd quarter worth about $4,180,000. Wellington Management Group LLP boosted its position in shares of BioAge Labs by 39.9% during the second quarter. Wellington Management Group LLP now owns 94,656 shares of the company's stock valued at $2,320,000 after buying an additional 26,975 shares during the period. Stonepine Capital Management LLC bought a new position in shares of BioAge Labs during the second quarter valued at approximately $490,200. Public Employees Retirement System of Ohio bought a new position in shares of BioAge Labs during the second quarter valued at approximately $681,000. Finally, Corient Private Wealth LP purchased a new stake in shares of BioAge Labs in the second quarter worth approximately $987,000.

BioAge Labs Stock Performance

BioAge Labs stock opened at $9.73 on Thursday. The company has a market capitalization of $446.61 million, a PE ratio of -4.09 and a beta of 0.94. The company has a 50 day moving average price of $17.05 and a 200-day moving average price of $17.95. BioAge Labs, Inc. has a fifty-two week low of $4.55 and a fifty-two week high of $25.95.

BioAge Labs (NASDAQ:BIOA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.07. The company had revenue of $2.45 million for the quarter. BioAge Labs had a negative return on equity of 28.99% and a negative net margin of 912.26%. On average, analysts forecast that BioAge Labs, Inc. will post -2.45 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Weiss Ratings restated a "sell (d-)" rating on shares of BioAge Labs in a report on Tuesday, July 21st. Roth Capital reiterated a "buy" rating and issued a $25.00 target price on shares of BioAge Labs in a research note on Friday, July 31st. Jefferies Financial Group set a $21.00 target price on BioAge Labs in a research report on Friday, July 31st. BTIG Research reissued a "buy" rating and set a $40.00 target price on shares of BioAge Labs in a research note on Monday, August 3rd. Finally, Wall Street Zen cut shares of BioAge Labs from a "hold" rating to a "sell" rating in a report on Sunday, May 17th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $36.57.

About BioAge Labs

BioAge Labs NASDAQ: BIOA is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.

Want to see what other hedge funds are holding BIOA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioAge Labs, Inc. (NASDAQ:BIOA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.